According to a report,” Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TMS, DBS, VBS), By Indication (MDD, OCD, Phobia), And Segment Forecasts, 2018 – 2025 ” , published by Grand View Research, Inc., The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025.The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years.
Key Takeaways from the report:
Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment’s growth is expected to wane
Patent expiration of branded medicines and introduction of generic biosimilars, which are cost effective, are responsible for the shrinking market of antidepressants
On the other hand, introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, are predicted to fuel the demand for therapeutics in the coming years
Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
Cognitive behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment
Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013
North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical
The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period.
U.S. Anxiety Disorders & Depression Treatment Market, By Product, 2014 – 2025 (USD Billion)
Browse More Reports in Pharmaceuticals Industry:
Nanocapsules Market : Rising incidences of chronic diseases worldwide, has created a demand for novel and effective drug delivery systems capable of delivering the required quantity of drug on the site of action at specific time. Nanocapsules are attributed to render significant results thereby avoiding side effects.
Browse Latest Research Insight in Pharmaceuticals Industry:
The Future of Ophthalmology Drugs Market : The worldwide ophthalmology drugs market was roughly valued at USD 11 billion in 2015 and estimated to reach USD 16 billion by 2020. The strength and attractive view of the market is supported by (1) Favorable macro trends, (2) Scientific innovation, and (3) increasing interest and focus on ophthalmology.
Anxiety Disorder and Depression Treatment Market Share, by Region, 2015
The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.
Grand View Research has segmented the anxiety disorders and depression treatment market by product, indication, and region:
Anxiety Disorder and Depression Treatment Product Outlook (Revenue, USD Million, 2014 – 2025)
Antidepressant drugs
SSRIs
SNRIs
TCAs
MAOIs
Atypical Antipsychotics
Benzodiazepines
Anticonvulsants
Beta-Blockers
Others
Therapy & Devices
Fischer Wallace Stimulator
TMS
DBS
VNS
ECT
CBT
Anxiety Disorder and Depression Treatment Indication Outlook (Revenue, USD Million, 2014 – 2025)
MDD
OCD
Phobias
Anxiety Disorder and Depression Treatment Regional Outlook (Revenue, USD Million, 2014 – 2025)
North America
U.S
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
The Middle East and Africa
South Africa
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media ContactCompany Name: Grand View Research, Inc.Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.Email: Send EmailPhone: 1-415-349-0058, Toll Free: 1-888-202-9519Address:201, Spear Street, 1100 City: San FranciscoState: CaliforniaCountry: United StatesWebsite: www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market